4/A//SEC Filing
Halak Brian K 4/A
Accession 0000904454-18-000697
CIK 0001399529other
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 10:05 AM ET
Size
18.3 KB
Accession
0000904454-18-000697
Insider Transaction Report
Form 4/AAmended
Halak Brian K
Director10% Owner
Transactions
- Sale
Common Stock
2018-10-30$14.31/sh−678$9,702→ 23,996 total(indirect: By DP VIII Associates, L.P.) - Sale
Common Stock
2018-10-30$13.68/sh−1,136$15,540→ 24,674 total(indirect: By DP VIII Associates, L.P.) - Sale
Common Stock
2018-10-31$13.60/sh−959$13,042→ 23,037 total(indirect: By DP VIII Associates, L.P.) - Sale
Common Stock
2018-10-30$13.68/sh−152,364$2,084,340→ 3,327,511 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-11-01$13.37/sh−188,867$2,525,152→ 2,919,056 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-10-30$14.31/sh−90,918$1,301,037→ 3,236,593 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-10-31$13.60/sh−128,670$1,749,912→ 3,107,923 total(indirect: By Domain Partners VIII, L.P.) - Sale
Common Stock
2018-11-01$13.37/sh−1,408$18,825→ 21,629 total(indirect: By DP VIII Associates, L.P.)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $14.2499. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The Reporting Person is a Managing Member of One Palmer Square Associates VIII, LLC, which is the sole general partner of Domain Partners VIII, L.P. and DP VIII Associates, L.P. Pursuant to Instruction (4)(b)(iv) of Form 4, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his pecuniary interest therein and/or that are not actually distributed to him.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $14.19. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.04 to $13.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]This amendment is being filed solely to correct a typographical error in this share number as reported in the Form 4 filed on November 1, 2018.
Documents
Issuer
Dicerna Pharmaceuticals Inc
CIK 0001399529
Entity typeother
Related Parties
1- filerCIK 0001354718
Filing Metadata
- Form type
- 4/A
- Filed
- Nov 4, 7:00 PM ET
- Accepted
- Nov 5, 10:05 AM ET
- Size
- 18.3 KB